Table 7.

Application of the proposed methods for the determination of the studied drugs in pharmaceutical preparations

Pharmaceutical preparations	Proposed methods			Reference methods
	Amount taken (μg/ml)	Amount found (μg/ml)	Recovery (%)	Taken (μg/ml)	Recovery (%)
At 610 nm
Glucobay 50 tabletsa	5.0	5.008	100.16
(Acarbose, 50 mg/tablet)	10.0	10.091	100.91
	15.0	15.218	101.45
x ± S.D.			100.84 ± 0.648	100.400 ± 0.400
t			1.002	(2.776)c
F			2.62	(19.00)
Glyset 50 mg tabletsb	2.0	1.978	98.90	60.0	97.26
(Miglitol, 50 mg/tablet)	4.0	4.025	100.63	80.0	98.71
	8.0	8.099	101.24	100.0	99.66
x ± S.D.			100.26 ± 1.214	98.54 ± 1.208
t			1.740	(2.776)c
F			1.01	(19.00)
At 525 nm
Glucobay 50 tablets	4.0	4.044	101.10
(Acarbose, 50 mg/tablet)	10.0	10.062	100.62
	20.0	20.220	101.10
x ± S.D.			100.94 ± 0.277	100.400 ± 0.400
t			1.923	(2.776)c
F			2.086	(19.00)
Glyset 50 mg tablets	2.0	1.987	99.35	60.0	97.26
(Miglitol, 50 mg/tablet)	4.0	4.070	101.75	80.0	98.71
	8.0	8.036	100.45	100.0	99.66
x ± S.D.			100.52 ± 1.201	98.54 ± 1.208
t			2.014	(2.776)c
F			1.01	(19.00)

Each result is the average of three separate determinations.

^aProduct of Alkan Pharma S.A.E., Egypt under licence of Bayer-Leverkusen, Germany, Egypt;

^bProduct of Sigma Pharma-ceutical industries, Egypt;

^cFigures in parentheses are the tabulated t and F values, respectively at p=0.05 (32).